Stock listing

OTC:ADRMF Adherium Ltd. Stock

US listing (OTC) of Adherium Ltd. · home listing ASX:ADR

Follow Adherium Ltd. into a list and get an email when it puts out news.

Home listing price · ASX:ADR

$0.048 AUD 0.000 (0.0%)

Close on Nov 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, ASX:ADR

Past year -88.0% · daily closes, Nov 20, 2025 – Nov 19, 2026, adjusted for splits
Day range
$0.048 – $0.048 AUDNov 19, 2026
Volume
48 sharesNov 19, 2026
Market cap
$2.63M AUDAt the close on Nov 19, 2026 · price × 54.89M shares outstanding
52-week range
$0.048 – $0.800 AUDLowest and highest trades, Nov 20, 2025 – Nov 19, 2026
Traded on an average day
$2,965 AUDMedian day 7,515 shares · last 3 months, Aug 21, 2026 – Nov 19, 2026
Adherium Ltd. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
ASX:ADR · Home$0.048 AUD0.000 (0.0%)48$0.048$0.048$0.048$0.048Close on Nov 19, 2026

Daily closes

Last 3 months, Aug 21, 2026 – Nov 19, 2026 · ASX:ADR · AUD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.0480.0000.0%$0.048$0.048$0.04848
$0.0480.0000.0%$0.048$0.048$0.04848
$0.048-0.002-4.0%$0.050$0.050$0.048109,028
$0.050-0.002-3.8%$0.052$0.052$0.05069,391
$0.0520.0000.0%$0.053$0.053$0.05280,252
$0.052-0.009-14.8%$0.055$0.055$0.052276,115
$0.061-0.006-9.0%$0.061$0.061$0.06118
$0.0670.0000.0%$0.068$0.068$0.0677,515
$0.067+0.004+6.3%$0.063$0.067$0.06372,078
$0.063-0.007-10.0%$0.069$0.069$0.060238,410
$0.0700.0000.0%$0.070$0.070$0.070127,404
$0.0700.0000.0%$0.070$0.070$0.070319
$0.0700.0000.0%$0.070$0.070$0.07037,500
$0.0700.0000.0%$0.072$0.072$0.07032,453
$0.070-0.007-9.1%$0.078$0.078$0.070169,585
$0.077+0.002+2.7%$0.076$0.077$0.0767,207
$0.075-0.001-1.3%$0.076$0.077$0.0756,758
$0.076-0.006-7.3%$0.076$0.076$0.07577,992
$0.0820.0000.0%$0.082$0.082$0.082316
$0.0820.0000.0%$0.082$0.082$0.082316
$0.0820.0000.0%$0.082$0.082$0.082300
$0.0820.0000.0%$0.082$0.082$0.0825,292
$0.0820.0000.0%$0.082$0.082$0.08219,173
$0.082+0.002+2.5%$0.082$0.082$0.08232,327
$0.080-0.002-2.4%$0.080$0.082$0.08093,856
$0.082-0.003-3.5%$0.084$0.084$0.08271,459
$0.0850.0000.0%$0.085$0.085$0.0855,882
$0.0850.0000.0%$0.085$0.085$0.0854
$0.085-0.015-15.0%$0.085$0.085$0.085141,469
$0.100+0.001+1.0%$0.098$0.100$0.09822,390
$0.099-0.001-1.0%$0.099$0.099$0.099199
$0.1000.0000.0%$0.100$0.100$0.100500
$0.1000.0000.0%$0.100$0.100$0.100500
$0.1000.0000.0%$0.099$0.100$0.09511,724
$0.1000.0000.0%$0.100$0.100$0.10022
$0.1000.0000.0%$0.100$0.100$0.10050
$0.1000.0000.0%$0.100$0.100$0.10050
$0.1000.0000.0%$0.100$0.100$0.1001,563
$0.1000.0000.0%$0.100$0.100$0.10010,017

Splits

3 splits since 2023 · ASX:ADR · every price before a split is adjusted for it

DayRatioWhat
1-for-100Consolidation
7-for-6Split
1-for-15Consolidation
Ticker
OTC:ADRMF
Asset type
Stock
Sector
Health care
Industry
Health care services
Exchange
OTC
Currency
USD

What changed lately

Latest news

All Adherium Ltd. news

Adherium Ltd. on 6ix

Sector
Health care
Industry
Health care services
News releases
30 in the last 12 months · 127 in all · newest Nov 19, 2026 · oldest 2016
Decks
32 decks · latest July 2026

Where Adherium Ltd. is listed

ListingExchangeCountryCurrency
ASX:ADR · Home listingASXAustraliaAUD
OTC:ADRMF · This pageOTCUnited StatesUSD

Valuation

EV/sales 7.0× against a median of 0.9×: 8th lowest of 9 Health care services companies shown. Statements: Year to Jun 30, 2025 · price Nov 19, 2026

Enterprise value
$5.71M AUD
P/E
Loss
EV/sales
7.0×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
13.6%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
Negative equity
Beta
No index for this market yet

Health care services: the 10 companies nearest in size, of 419 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Adherium Ltd. · ASX:ADRUS$1.74MUS$3.78Mn/a7.0×n/an/an/an/an/a
Feedback plc · LSE:FDBKUS$2.24M−US$2.77Mn/a−2.4×n/a0.4×−826.2%0.0×n/a
Predilife SA · EURONEXT:ALPREUS$2.16MUS$7.61Mn/a6.2×n/an/a−315.3%n/an/a
RMH Holdings Limited · HKEX:8437US$2.12MUS$2.58Mn/an/an/an/an/an/an/a
INVO Fertility, Inc. · NASDAQ:IVFUS$2.10MUS$3.06Mn/a0.4×n/a0.1×−71.4%0.1×1.62
HealthLynked Corp. · OTC:HLYKUS$2.07MUS$2.05Mn/a1.8×n/an/a−351.6%n/a-0.67
Grey Matters Health Inc · CSE:GREYUS$1.98MUS$1.95Mn/an/an/a1.6×n/a0.0×0.43
Global Health Limited · ASX:GLHUS$1.95MUS$2.54Mn/a0.5×n/an/a−10.5%n/an/a
Telemedycyna Polska S.A. · NEWCONNECT:TMPUS$1.76MUS$1.73Mn/a1.3×n/an/a−14.9%n/an/a
Accendra Health, Inc. · NYSE:ACHUS$1.57MUS$9.96Mn/a0.0×0.1×n/a−6.7%n/a0.51
CardioComm Solutions, Inc. · TSXV:EKGUS$1.38MUS$1.62Mn/a8.5×n/an/a−194.6%n/a0.00
Median of the othersUS$2.02MUS$2.30M0.9×0.1×0.4×−132.9%0.0×0.43

Forecasts

Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
0.89 AUD · Analysts' mean
EPS, year to Jun 2027
-0.098 · 1 analyst
Revenue, year to Jun 2027
9.61M · 1 analyst

Team and board

Officers

OfficerRole
Dawn BitzCEO
John PerryInterim Chief Executive Officer & Chief Commercial Officer
Brad WilsonChief Financial Officer
Daniel KaplonChief Financial Officer
Catherine MorganHead of Regulatory & Quality
David HaddadHead of Product
Hetal DhruveHead of Medical & Clinical Affairs

Board

DirectorRole
George BaranNon-Executive Chair
James Ward-LilleyChairman of the Board
Dawn BitzCEO
Jeremy Curnock CookIndependent Non-Executive Director
Keven GessnerNon-Executive Director
Lou PanaccioIndependent Non-Executive Director
Victoria DurransIndependent Non-Executive Director

Events

QuarterResultsShare move
Q4 2025Sep 30, 20250.0%
Q2 2025Feb 28, 2025−15.4%
Q2 2023Feb 27, 2023 · After close−14.3%
Q4 2022Aug 31, 2022 · Before open
Q2 2022Feb 25, 2022+9.1%
Q4 2021Aug 27, 2021−6.3%
Q2 2021Feb 25, 20210.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (July 2026)Investor deck24 slidesJuly 2026
Investor Webinar June 2026Conference19 slidesJune 2026
Investor Presentation (February 2026)Investor deck42 slidesFeb 16, 2026
Investor Presentation (February 2026)Investor deck36 slidesFebruary 2026
Investor Webinar (December 2025)Conference15 slidesDec 1, 2025
Shareholder Meeting (November 2025)Shareholder meeting30 slidesNov 18, 2025
Investor Presentation (October 2025)Investor deck26 slidesOctober 2025
Investor Presentation (February 2025)Investor deck31 slidesFebruary 2025
Investor Presentation (April 2024)Investor deck28 slidesApr 26, 2024
Shareholder Meeting (November 2023)Shareholder meeting18 slidesNov 30, 2023
All 32 decks
DeckKindSlidesDate
Investor Presentation (November 2023)Investor deck17 slidesNov 22, 2023
41st Annual J.P. Morgan Healthcare Conference 2023Conference19 slidesJan 10, 2023
Investor Presentation (October 2022)Investor deck11 slidesOct 21, 2022
Investor Presentation (August 2022)Investor deck18 slidesAugust 2022
Investor Presentation (April 2021)Investor deck10 slidesApril 2021
Investor Presentation (March 2021)Investor deck23 slidesMar 18, 2021
Shareholder Meeting (November 2020)Shareholder meeting13 slidesNovember 2020
Shareholder Meeting (July 2020)Shareholder meeting18 slidesJul 24, 2020
Investor Presentation (December 2019)Investor deck25 slidesDec 19, 2019
Shareholder Meeting (November 2019)Shareholder meeting15 slidesNovember 2019
Shareholder Meeting (November 2018)Shareholder meeting16 slidesNov 20, 2018
Investor Conference Call Q1 Fiscal Year 2019Conference13 slidesOct 31, 2018
FY2018 Earnings PresentationEarnings14 slidesAug 28, 2018
Q3 FY18 Earnings PresentationEarnings12 slidesMay 4, 2018
H1 2018 Earnings PresentationEarnings13 slidesFeb 8, 2018
Shareholder Meeting (November 2017)Shareholder meeting14 slidesNov 29, 2017
Conference Presentation (August 2017)Conference19 slidesAug 29, 2017
JP Morgan Conference 2017Conference15 slidesJan 11, 2017
AusBiotech 2016Conference4 slidesOct 26, 2016
Non-Deal Roadshow (October 2016)Roadshow20 slidesOct 26, 2016
H1 FY2016 Earnings PresentationEarnings33 slidesMar 7, 2016
EBD Biotech Showcase 2016Conference40 slidesJan 11, 2016

Open Decks

Financings

RaiseDateIn US dollars
Private placement of new shares
Closed: A$1.34M raised · A$0.003 a share · Stralis Capital Partners Pty Limited +2
Dealers: Stralis Capital Partners Pty Limited (lead), PAC Partners Securities Pty Ltd, Volatility Pty Ltd (InvestHouse)
Use of proceeds: Commercial initiatives focused on growth in the Remote Patient Monitoring channel and progress toward value-based care contracts with U.S. insurers
Feb 18, 2026US$945,779
Rights offering of new shares
Tranche closed: A$5.37M raised · A$0.003 a share · Stralis Capital Partners Pty Limited +2
Dealers: Stralis Capital Partners Pty Limited (lead), PAC Partners Securities Pty Ltd, Volatility Pty Ltd (InvestHouse)
Buyers: Trudell Medical Ltd (firm commitment of A$2.0 million, greater than its pro-rata entitlement under the Institutional Entitlement Offer)
Use of proceeds: Commercial initiatives focused on growth in the Remote Patient Monitoring channel and progress toward value-based care contracts with U.S. insurers
Feb 18, 2026US$3.79M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in AUD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue817.2K841.0K3.19M529.0K401.0K2.22M2.78M5.87M2.35M2.10M
Cost of revenue705.9K573.3K1.50M1.22M1.19M1.54M1.13M1.10M1.19M1.07M
Gross profit111.4K267.7K1.69M-690.0K-789.0K677.0K1.65M4.77M1.16M1.03M
Research and development3.44M4.14M4.72M5.88M5.48M3.95M5.12M4.45M4.24M2.17M
Selling, general and administrative5.49M5.06M4.85M5.36M6.14M3.77M4.34M5.41M6.26M3.12M
Operating income-12.5M-12.1M-11.9M-12.8M-12.4M-8.92M-11.6M-9.64M-13.8M-6.68M
Depreciation and amortization103.3K108.1K191.0K186.0K145.0K335.0K413.0K310.0K270.0K121.6K
EBITDA-12.4M-12.0M-11.7M-12.7M-12.2M-8.59M-11.2M-9.33M-13.6M-6.56M
Interest expense228.7K2.07K6.00K1.00K2.24M2.60M4.00K00303.2K
Income before tax-12.7M-10.2M-11.7M-12.9M-15.4M-11.4M-11.8M-9.34M-12.8M-6.31M
Income tax-1.19M-1.45M-1.84M-2.81M-370.0K128.7K91.1K-98.0K-883.0K0
Net income-12.7M-10.2M-9.86M-10.0M-15.0M-11.4M-11.8M-9.34M-12.8M-6.31M
Earnings per share, basic-1.41-2.75-3.62-6.93-25.03-54.10-1.02-80.76-0.08-75.51

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents43.3K6.20M9.08M5.28M15.2M4.58M763.0K12.1M22.8M27.2M
Short-term investments0427.0K
Receivables80.7K1.80M1.97M420.0K567.0K624.0K287.0K1.21M826.0K948.0K
Inventory1.84M1.58M1.24M1.07M962.0K1.12M417.0K509.0K726.0K418.0K
Current assets3.40M9.73M12.5M8.22M16.9M6.48M1.77M14.5M24.4M28.6M
Property, plant and equipment127.0K313.0K127.0K235.0K380.0K515.0K417.0K298.0K
Total assets3.52M9.89M12.7M8.53M17.0M6.72M2.24M15.3M25.1M29.0M
Accounts payable3.09M775.7K958.0K335.0K701.0K1.00M914.0K877.0K2.38M591.0K
Current liabilities8.25M3.35M3.47M2.95M3.00M3.33M1.41M2.51M2.39M1.50M
Long-term debt01.71M
Total debt3.12M93.2K44.0K85.0K
Total liabilities8.28M3.41M3.47M3.00M3.00M3.33M1.41M2.51M2.39M1.50M
Shareholders' equity-4.76M6.48M9.21M5.54M14.0M3.38M830.0K12.8M22.7M27.5M
Shares outstanding9.00M3.71M2.72M1.45M600.6K210.7K11.6M115.6K169.4M83.5K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-9.98M-10.6M-9.28M-9.61M-11.3M-7.32M-11.8M-9.82M-11.6M-7.91M
Capital spending-48.2K-37-41.0K-279.0K-29.0K-138.0K-325.0K-325.0K-564.0K-440.0K
Free cash flow-10.0M-10.6M-9.32M-9.89M-11.3M-7.46M-12.1M-10.1M-12.1M-8.35M
Cash from investing-48.2K-37-41.0K-279.0K-29.0K-138.0K111.0K-902.0K-564.0K-440.0K
Cash from financing3.87M7.73M13.1M1.43M21.9M11.3M11.3M71.0K7.56M31.9M
Dividends paid-20.9M-11.2M
Share buybacks-642.0K-744.0K0-968.0K-105.0K071.0K-511.0K35.4M
Change in cash-6.15M-2.88M3.79M-9.89M10.6M3.82M-11.4M-10.7M-4.43M23.7M

Open Financials

Filings

FilingDateTypeFiled with
Change in substantial holdingNov 19, 2026Ownership change noticeASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 30, 2026Quarterly reportASX
Quarterly Activities/Appendix 4C Cash Flow ReportOct 30, 2026Quarterly reportASX
Additional $750,000 Loan Facility from Barvest VenturesOct 30, 2026FinancingASX
Notice of Annual General Meeting/Proxy FormOct 28, 2026Meeting noticeASX
Partnership with Florida Lung, Asthma & Sleep SpecialistsOct 25, 2026Operations updateASX
Appointment of Chief Financial OfficerOct 11, 2026Management or board changeASX
AUD$700,000 Short-Term Loan Facility from Barvest VenturesOct 6, 2026Other filingsASX
Appendix 4G & Corporate Governance StatementSep 30, 2026Other filingsASX
Annual Report to shareholdersSep 30, 2026Annual reportASX
All 118 filings
FilingDateTypeFiled with
Adherium Consolidates Funding into A$4.67M Term LoanSep 15, 2026FinancingASX
Preliminary Final ReportAug 31, 2026Annual reportASX
Change of Company SecretaryAug 21, 2026Management or board changeASX
Adherium enters into additional $1M short-term loan facilityAug 17, 2026FinancingASX
Ceasing to be a substantial holderJul 30, 2026Ownership change noticeASX
Adherium Announces CEO TransitionJul 28, 2026Management or board changeASX
Quarterly Activities/Appendix 4C Cash Flow ReportJul 28, 2026Quarterly reportASX
Adherium - Investor UpdateJul 26, 2026Other filingsASX
Results of Extraordinary General MeetingJun 18, 2026Meeting outcomeASX
Notice of Share ConsolidationMay 20, 2026Other filingsASX
Adherium Hailie Smartinhaler Quarter-to-Date Sales UpdateMar 10, 2026ResultsASX
Half Yearly Report and AccountsFeb 27, 2026Interim reportASX
Completion of Placement and Institutional Entitlement OfferFeb 17, 2026FinancingASX
Placement and Accelerated Non-Renounceable Entitlement OfferFeb 15, 2026FinancingASX
Equity Raising Investor PresentationFeb 15, 2026FinancingASX
Trading HaltFeb 15, 2026Trading halt or suspensionASX
Quarterly Activities/Appendix 4C Cash Flow ReportJan 30, 2026Quarterly reportASX
Adherium exceeds CY2025 device shipment milestonesDec 23, 2025ResultsASX
Adherium quarter to date sales updateDec 15, 2025ResultsASX
Adherium reaches major milestone in Allergy Partners rolloutNov 26, 2025Operations updateASX
iCARE Study Hailie Smartinhaler Improves Patient AdherenceSep 15, 2025ResultsASX
Preliminary Final ReportAug 29, 2025ResultsASX
Firm commitments received for institutional placementAug 4, 2025FinancingASX
Adherium Appoints Dawn Bitz as CEOJul 22, 2025Management or board changeASX
Successful Completion of Retail Component of ANREOJul 17, 2025FinancingASX
Replacement ProspectusJun 26, 2025Offer documentASX
Successful Completion of Institutional Component of ANREOJun 26, 2025FinancingASX
ProspectusJun 24, 2025Offer documentASX
Accel Non-Renounceable Entitlement Offer to raise up to $4mJun 24, 2025FinancingASX
$900K Capital Raise to Accelerate Smart Inhaler in USMay 19, 2025FinancingASX
Adherium Secures $2.6M to Advance Smart Inhaler in USMar 18, 2025FinancingASX
Management ChangeOct 29, 2024Other filingsASX
AstraZeneca selected Adherium Smartinhaler for its studyMay 23, 2024Operations updateASX
Non-Renounceable Rights Issue Offer CompletesMay 23, 2024FinancingASX
Placement and Entitlement Offer to raise up to $8.37 millionApr 26, 2024FinancingASX
First Patient Enrolled in Major e-health Clinical StudyMar 19, 2024Operations updateASX
Adherium receives $1.5m Australian R&D Tax RebateMar 6, 2024ResultsASX
New CEO Appointed - Dr Paul MastoridisJan 31, 2024Management or board changeASX
Resignation of CEOJan 15, 2024Management or board changeASX
Notice of Annual General Meeting/Proxy FormOct 26, 2023Meeting noticeASX
Annual Report to shareholdersAug 30, 2023Annual reportASX
Adherium SPP and Shortfall Offers ProspectusNov 17, 2022Offer documentASX
Adherium secures $13.5m in placement commitmentsSep 16, 2022FinancingASX
Adherium signs UK distribution agreement with Helicon HealthJun 14, 2022Other filingsASX
Adherium to support Avillion sponsored clinical studyJun 1, 2022Other filingsASX
Adherium awarded US-based AZ clinical study supply contractSep 24, 2021Other filingsASX
Target's StatementJun 28, 2021Offer documentASX
Letter to Shareholders re takeover offerJun 16, 2021Acquisition or disposalASX
Adherium submits next gen sensor for US FDA clearanceMay 31, 2021Other filingsASX
Replacement Bidders StatementMay 27, 2021Offer documentASX
1st Supplementary Bidder's Statement(marked up replacementMay 27, 2021Offer documentASX
Adherium announces new CEO and Board appointmentsMay 12, 2021Management or board changeASX
Adherium Directors' Statement re TakeoverMay 10, 2021Acquisition or disposalASX
Appendix 4C - quarterlyApr 30, 2021Quarterly reportASX
Adherium response to Respiri announcementApr 29, 2021Other filingsASX
Bidder's StatementApr 29, 2021Offer documentASX
Adherium investor presentationMar 17, 2021Other filingsASX
Adherium secures $18m share placement commitmentMar 17, 2021FinancingASX
Adherium agrees rollout to specialist US respiratory centresNov 23, 2020Other filingsASX
Adherium secures $3m funding from ViburnumOct 25, 2020Other filingsASX
CEO update presentation to the EGMJul 23, 2020Other filingsASX
Adherium $5m raise with BioScience Managers Translation FundMay 25, 2020Other filingsASX
Adherium progresses US sales agreement with Monaghan MedicalApr 29, 2020Other filingsASX
Adherium appoints Mike Motion CEO/Director and Anne Bell CFOApr 24, 2020Other filingsASX
Adherium and Planet Innovation partner in tech developmentApr 21, 2020Other filingsASX
Adherium announces collaboration with HGE Health in COPDApr 16, 2020Other filingsASX
Adherium Completes $5.4m Capital RaiseFeb 10, 2020Other filingsASX
Adherium December 2019 Update PresentationDec 18, 2019Other filingsASX
Adherium Non-renounceable Rights Issue Offer DocumentDec 18, 2019FinancingASX
Adherium announces Non-Renounceable IssueDec 10, 2019Other filingsASX
Adherium appoints Peter Stratford CEO and Mike Motion CCONov 21, 2019Other filingsASX
Adherium and Patients Know Best strategic collaborationNov 17, 2019Other filingsASX
Amended - Adherium announces $1.1m notes financingNov 11, 2019Other filingsASX
Response to ASX QueryNov 10, 2019Explanation requestASX
Adherium announces $1.8m secured notes financingAug 21, 2019Other filingsASX
Adherium and Summatix announce strategic initiativeAug 20, 2019Other filingsASX
Adherium Receives further U.S. 510k ClearancesJul 15, 2019Other filingsASX
Employee Share Plan buy-back - Appendix 3CMay 24, 2019Treasury share statusASX
Response to Appendix 4C QueryMay 6, 2019Quarterly reportASX
Adherium Restructures for GrowthDec 12, 2018Other filingsASX
Adherium Investor Conference Call PresentationOct 30, 2018Other filingsASX
Adherium and Vitalus Health Launch Commercial ProgramAug 23, 2018Other filingsASX
Adherium Receives Additional US FDA 510(k) ClearanceJul 26, 2018Other filingsASX
Adherium Program with Connecticut Childrens Medical CenterJul 10, 2018Other filingsASX
Adherium Smartinhaler used in Global Mild-Asthma StudiesMay 21, 2018Other filingsASX
Adherium launches new global brand HailieMay 16, 2018Other filingsASX
Adherium Announces Program with Vitalus HealthMay 1, 2018Other filingsASX
Adherium receives US FDA 510k OTC clearanceMar 27, 2018Other filingsASX
Asthma Adherence Management FindingsMar 7, 2018Other filingsASX
Adherium Highlights Milestones AchievedDec 20, 2017Other filingsASX
Presentation to AGMNov 29, 2017Other filingsASX
Adherium receives US FDA 510k clearanceAug 31, 2017Other filingsASX
Investor Conference Call PresentationAug 28, 2017Other filingsASX
Commitments Test Entity - Fourth Quarter ReportJul 31, 2017Other filingsASX
Adherium Appoints New CEO to Drive Global GrowthJun 8, 2017Management or board changeASX
Appendix 4C - quarterly December 2016Jan 29, 2017Quarterly reportASX
NICE reports on Adherium Smartinhaler for asthma managementJan 11, 2017Other filingsASX
Adherium Smartinhaler dramatically improves outcomesNov 17, 2016Other filingsASX
Appendix 4C - quarterly for period ended 30 Sept 2016Oct 31, 2016Quarterly reportASX
Key Technology Patent Granted in USOct 19, 2016Other filingsASX
Adherium and AstraZeneca Australia Commercial Pilot ProgramAug 16, 2016Other filingsASX
Adherium Executes Placement to Fidelity InternationalJul 19, 2016FinancingASX
Adherium Smartinhaler in AstraZeneca COPD StudyJun 13, 2016Other filingsASX
Clearance to Market in Canada for Flagship ProductsMar 15, 2016Other filingsASX
Appendix 4D and Interim Consolidated Financial ReportFeb 29, 2016Interim reportASX
Adherium Smartinhaler Technology in Multinational StudyFeb 26, 2016Other filingsASX
New Clinical Data Presented at ERS 2015Feb 11, 2016Other filingsASX
Admission to Official ListFeb 10, 2016Other filingsASX

Open Filings

Cap table

Built by 6ix from Adherium Ltd.’s releases · as of Feb 18, 2026

Common shares
54,887,674
Fully diluted
54,887,674

Fully diluted

LineShares
Common shares54,887,674

Share count over time

CountShares
Nov 22, 202654,887,674
May 20, 2026

Open Cap table

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Brad WilsonChief Financial Officer · Since at least Oct 11, 2026
Catherine MorganHead of Regulatory & Quality · Since at least Nov 4, 2026
Daniel KaplonChief Financial Officer · Since at least Nov 5, 2026
David HaddadHead of Product · Since at least Nov 4, 2026
Dawn BitzCEO · Since at least Sep 16, 2025
George BaranNon-Executive Chair · Since at least Nov 5, 2026
Hetal DhruveHead of Medical & Clinical Affairs · Since at least Nov 4, 2026
James Ward-LilleyChairman of the Board · Since at least Nov 5, 2026
Jeremy Curnock CookIndependent Non-Executive Director · Since at least Nov 5, 2026
John PerryInterim Chief Executive Officer & Chief Commercial Officer · Since at least Nov 4, 2026
All 13 people
PersonSeat
Keven GessnerNon-Executive Director · Since at least Nov 4, 2026
Lou PanaccioIndependent Non-Executive Director · Since at least Nov 4, 2026
Victoria DurransIndependent Non-Executive Director · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Adherium Ltd.